Johnson & Johnson ICOTYDE long-term data show two-year psoriasis results

On October 9, 2026, J&J reported Phase 3 data presented at Fall Clinical Dermatology: nearly three-quarters of adults and adolescents achieved clear or almost clear skin at two years, with a continued favorable safety profile.